AR004255A1 - Formulacion liofilizada farmaceuticamente aceptable constituida por una fase amorfa y una fase cristalina, que comprende por lo menos un principio activo no proteico, y procedimiento para estabilizar el principio activo no proteico contenido en la formulacion liofilizada farmaceuticamente aceptable - Google Patents
Formulacion liofilizada farmaceuticamente aceptable constituida por una fase amorfa y una fase cristalina, que comprende por lo menos un principio activo no proteico, y procedimiento para estabilizar el principio activo no proteico contenido en la formulacion liofilizada farmaceuticamente aceptableInfo
- Publication number
- AR004255A1 AR004255A1 ARP960104998A ARP960104998A AR004255A1 AR 004255 A1 AR004255 A1 AR 004255A1 AR P960104998 A ARP960104998 A AR P960104998A AR P960104998 A ARP960104998 A AR P960104998A AR 004255 A1 AR004255 A1 AR 004255A1
- Authority
- AR
- Argentina
- Prior art keywords
- lyophilized
- protetic
- stabilize
- pharmaceutically acceptable
- procedure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención tiene por objeto una formulación liofilizada constituida por una fase amorfa y una fase cristalina, farmacéuticamente aceptable quecomprende por lo menos un principio activo no proteico, caracterizado porque contiene manitol yalani na en una relación R comprendida entre 0,1 I,representando R la masa de manitol sobre la masa de alanina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9513022A FR2740686B1 (fr) | 1995-11-03 | 1995-11-03 | Formulation pharmaceutique lyophilisee stable |
Publications (1)
Publication Number | Publication Date |
---|---|
AR004255A1 true AR004255A1 (es) | 1998-11-04 |
Family
ID=9484220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960104998A AR004255A1 (es) | 1995-11-03 | 1996-11-01 | Formulacion liofilizada farmaceuticamente aceptable constituida por una fase amorfa y una fase cristalina, que comprende por lo menos un principio activo no proteico, y procedimiento para estabilizar el principio activo no proteico contenido en la formulacion liofilizada farmaceuticamente aceptable |
Country Status (32)
Country | Link |
---|---|
US (1) | US6284277B1 (es) |
EP (1) | EP0858325B1 (es) |
JP (1) | JP3357376B2 (es) |
KR (1) | KR100367752B1 (es) |
CN (1) | CN1124844C (es) |
AR (1) | AR004255A1 (es) |
AT (1) | ATE221374T1 (es) |
AU (1) | AU713383B2 (es) |
BR (1) | BR9611367A (es) |
CA (1) | CA2234140C (es) |
CZ (1) | CZ287178B6 (es) |
DE (1) | DE69622735T2 (es) |
DK (1) | DK0858325T3 (es) |
EE (1) | EE04293B1 (es) |
ES (1) | ES2180805T3 (es) |
FR (1) | FR2740686B1 (es) |
HK (1) | HK1015697A1 (es) |
IL (1) | IL124214A (es) |
IS (1) | IS1967B (es) |
MX (1) | MX9803344A (es) |
MY (1) | MY116578A (es) |
NO (1) | NO322582B1 (es) |
NZ (1) | NZ321616A (es) |
PL (1) | PL186284B1 (es) |
PT (1) | PT858325E (es) |
RU (1) | RU2163801C2 (es) |
SK (1) | SK283031B6 (es) |
TR (1) | TR199800782T2 (es) |
TW (1) | TW442295B (es) |
UA (1) | UA60297C2 (es) |
WO (1) | WO1997017064A1 (es) |
ZA (1) | ZA969176B (es) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6743777B1 (en) * | 1992-03-19 | 2004-06-01 | Eli Lilly And Company | Cyclic peptide antifungal agents and process for preparation thereof |
US6197787B1 (en) * | 1997-03-03 | 2001-03-06 | Sanofi-Synthelabo | Pharmaceutical formulations containing poorly soluble drug substances |
JP4939680B2 (ja) * | 1997-05-27 | 2012-05-30 | 武田薬品工業株式会社 | 固形製剤 |
FR2764800B1 (fr) * | 1997-06-23 | 1999-09-10 | Sanofi Sa | Composition pharmaceutique solide contenant des derives de benzofuranne |
SE9702680D0 (sv) * | 1997-07-11 | 1997-07-11 | Astra Pharma Prod | New formulation |
DE19754324A1 (de) * | 1997-12-08 | 1999-06-10 | Byk Gulden Lomberg Chem Fab | Neue Darreichungsform enthaltend einen säurelabilen Wirkstoff |
JP4546643B2 (ja) | 1997-12-08 | 2010-09-15 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 酸不安定な活性化合物を含有する新規の坐剤形 |
GB9804013D0 (en) * | 1998-02-25 | 1998-04-22 | Sanofi Sa | Formulations |
FR2781227B1 (fr) * | 1998-07-20 | 2002-02-22 | Sanofi Sa | Procede pour la preparation du sel potassique du lintitript |
FR2782455B3 (fr) * | 1998-08-20 | 2000-09-15 | Sanofi Sa | Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine |
US6898762B2 (en) | 1998-08-21 | 2005-05-24 | United Video Properties, Inc. | Client-server electronic program guide |
FR2787329B1 (fr) * | 1998-12-17 | 2001-02-09 | Aventis Pharma Sa | Nouvelle application therapeutique des heparines de bas poids moleculaire |
EP1156782B1 (en) * | 1999-03-03 | 2005-05-04 | Eli Lilly And Company | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
CN1345333A (zh) * | 1999-03-03 | 2002-04-17 | 伊莱利利公司 | 棘白菌素/糖类复合物 |
FR2793685B1 (fr) * | 1999-05-19 | 2001-08-24 | Promindus Actions Promotionnel | Compositions pharmaceutiques, destinees a l'administration par voie orale de phloroglucinol et leur preparation |
FR2805539B1 (fr) * | 2000-02-25 | 2005-06-10 | Oreal | Compositions de teinture des fibres keratiniques contenant des derives d'indolizine et procede de teinture |
US6716884B1 (en) | 2000-05-19 | 2004-04-06 | Promindus (Actions Promotionnelles Dans L'industrie Et Le Commerce) | Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof |
US7396841B2 (en) | 2000-08-18 | 2008-07-08 | Takeda Pharmaceutical Company Limited | Injections |
MY137726A (en) * | 2000-11-22 | 2009-03-31 | Nycomed Gmbh | Freeze-dried pantoprazole preparation and pantoprazole injection |
AU2002224063A1 (en) * | 2000-11-24 | 2002-06-03 | Yamanouchi Pharmaceutical Co..Ltd. | Water-soluble liquid internal medicine |
CA2465597A1 (en) * | 2001-11-14 | 2003-06-12 | Ben Zion Dolitzky | Amorphous and crystalline forms of losartan potassium and process for their preparation |
CA2469656A1 (en) * | 2001-12-10 | 2003-06-19 | Dr. Reddy's Laboratories Limited | Amorphous form of 2-n-butyl-3-( (2-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl) methyl) -1,3-diazaspiro (4,4') non-1-en-4-one |
ATE397440T1 (de) | 2002-02-22 | 2008-06-15 | Schering Corp | Pharmazeutische zubereitungen von antineoplastischen wirkstoffen, insbesondere temozolomid, verfahren zu ihrer herstellung und deren verwendung |
US20040022842A1 (en) * | 2002-06-03 | 2004-02-05 | Mebiopharm Co., Ltd. | Liposome preparations containing oxaliplatin |
US6991800B2 (en) * | 2002-06-13 | 2006-01-31 | Vicuron Pharmaceuticals Inc. | Antifungal parenteral products |
GB2393181A (en) * | 2002-09-19 | 2004-03-24 | Cipla Ltd | Amorphous clopidogrel |
CN100348596C (zh) | 2002-10-03 | 2007-11-14 | 霍夫曼-拉罗奇有限公司 | 作为葡糖激酶(gk)激活剂的吲哚-3-甲酰胺 |
RU2350602C2 (ru) * | 2002-12-03 | 2009-03-27 | Ф.Хоффманн-Ля Рош Аг | Аминоалкоксииндолы, как лиганды рецептора 5-нт6, для лечения заболеваний цнс |
DE10305984A1 (de) * | 2003-02-13 | 2004-09-02 | Helm Ag | Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen |
GB0304636D0 (en) * | 2003-02-28 | 2003-04-02 | Britannia Pharmaceuticals Ltd | Pharmaceutical composition for nasal delivery |
KR100732100B1 (ko) * | 2003-05-07 | 2007-06-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 메틸코발라민 함유 동결 건조 제제 및 그의 제조 방법 |
JP2007504177A (ja) * | 2003-09-02 | 2007-03-01 | プリヴァ−ラケマ,エー.エス. | 医薬組成物、その製造方法及び治療上の使用 |
WO2005065185A2 (en) * | 2003-12-24 | 2005-07-21 | Collegium Pharmaceuticals, Inc. | Temperature-stable formulations, and methods of development thereof |
US20050255161A1 (en) * | 2004-05-10 | 2005-11-17 | Servet Buyuktimkin | Method for the long term stabilization of labile compounds at room temperature in pharmaceutical preparations containing water |
DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
US20060275331A1 (en) * | 2004-08-31 | 2006-12-07 | Borek Zaludek | Pharmaceutical composition, method of manufacturing and therapeutic use thereof |
WO2006050389A2 (en) | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds, compositions and methods |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
US20070026026A1 (en) * | 2005-08-01 | 2007-02-01 | David Delmarre | Oral liquid losartan compositions |
EP1787641A1 (de) * | 2005-11-22 | 2007-05-23 | Helm AG | Tazobactam-Piperacillin-Lyophilisat |
US20080108664A1 (en) * | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
WO2007103711A2 (en) * | 2006-03-01 | 2007-09-13 | Dr. Reddy's Laboratories Ltd. | Polymorphic forms of rimonabant |
WO2007146652A1 (en) * | 2006-06-06 | 2007-12-21 | Threshold Pharmaceuticals, Inc. | Unit dose form of glufosfamide |
US20070287734A1 (en) * | 2006-06-09 | 2007-12-13 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity |
CA2668834C (en) | 2006-11-07 | 2016-10-11 | Sanofi Pasteur Biologics Co. | Stabilization of vaccines by lyophilization |
US20100062066A1 (en) * | 2006-11-14 | 2010-03-11 | Acusphere, Inc | Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration |
US8765690B2 (en) * | 2007-04-05 | 2014-07-01 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with glufosfamide in patients not receiving insulin therapy |
GB0715285D0 (en) * | 2007-08-06 | 2007-09-12 | Britannia Pharmaceuticals Ltd | Improvements in or relating to powdered medicaments for nasal delivery |
DE602008002820D1 (de) | 2008-04-25 | 2010-11-11 | Sandoz Ag | Hydrogensulfat von 2-Acetoxy-5-(a-cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7-tetrahydrothienoÄ3,2-cÜpyridin und dessen Zubereitung |
WO2011034394A2 (ko) | 2009-09-21 | 2011-03-24 | 주식회사 중외제약 | 옥살리플라틴의 나노 입자 및 이를 제조하는 방법 |
WO2011101865A2 (en) | 2010-02-19 | 2011-08-25 | Cadila Healthcare Limited | Stable pharmaceutical compositions of clopidogrel for parenteral delivery |
RU2647972C2 (ru) | 2010-05-12 | 2018-03-21 | Ремпекс Фармацеутикалс, Инк. | Тетрациклиновая композиция |
WO2013105998A2 (en) | 2011-02-16 | 2013-07-18 | Tyco Electronics Corporation | Fiber optic closure |
MX362344B (es) | 2011-04-15 | 2019-01-11 | Janssen Pharmaceutica Nv | Nanosuspensiones de farmacos secadas por congelamiento. |
CN103230371B (zh) * | 2012-05-18 | 2014-07-23 | 湖北一半天制药有限公司 | 注射用奥沙利铂冻干制剂的制备方法 |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
CN106706785B (zh) * | 2016-12-23 | 2019-02-26 | 东药集团沈阳施德药业有限公司 | 一种采用高效液相色谱检测厄贝沙坦氢氯噻嗪片中有关物质的方法 |
US10149857B2 (en) | 2017-03-09 | 2018-12-11 | Ampac Fine Chemicals Llc | Lyophilized cyclophosphamide composition and methods of preparation thereof |
US11110063B2 (en) | 2017-08-25 | 2021-09-07 | MAIA Pharmaceuticals, Inc. | Storage stable sincalide formulations |
MX2020005879A (es) | 2017-12-07 | 2020-10-07 | Reven Ip Holdco Llc | Composiciones administrables vía intravenosa que comprenden ácidos de grado farmacéutico y reguladores del ph, y el uso de las mismas para tratar enfermedades de disfunción mitocondrial, enfermedades metabólicas y de disfunción del modelado de huesos y tejidos. |
WO2023012479A1 (en) | 2021-08-03 | 2023-02-09 | Liqmeds Worldwide Limited | An oral pharmaceutical solution of clopidogrel |
CN114533683B (zh) * | 2021-12-23 | 2023-08-01 | 李宏 | 一种注射用腺苷钴胺冻干制剂组合物及其制备方法 |
TW202339745A (zh) | 2022-01-28 | 2023-10-16 | 大陸商上海柯君醫藥科技有限公司 | 抗血小板藥物的藥物組合物及其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS532931B2 (es) * | 1973-12-05 | 1978-02-01 | ||
GB2021581B (en) * | 1978-05-17 | 1982-10-20 | Wellcome Found | Stabilisation of pgl derivatives |
US4537883A (en) * | 1982-11-12 | 1985-08-27 | Mead Johnson & Company | Lyophilized cyclophosphamide |
JPH0296536A (ja) * | 1988-09-29 | 1990-04-09 | Green Cross Corp:The | プラスミノゲン乾燥製剤 |
CA2013474C (en) * | 1989-04-20 | 2000-01-18 | Pharmacia Inc. | Cyclophosphamide - alanine lyophilizates |
US5558880A (en) | 1989-12-22 | 1996-09-24 | Janssen Pharmaceutica Inc. | Pharmaceutical and other dosage forms |
IL105553A (en) * | 1992-05-06 | 1998-01-04 | Janssen Pharmaceutica Inc | Solid dosage forms consisting of a porous network of matrix that releases a substance that dissipates rapidly in water |
US5885486A (en) * | 1993-03-05 | 1999-03-23 | Pharmaciaand Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
FR2719479B1 (fr) * | 1994-05-04 | 1996-07-26 | Sanofi Elf | Formulation stable lyophilisée comprenant une protéine: kit de dosage. |
-
1995
- 1995-11-03 FR FR9513022A patent/FR2740686B1/fr not_active Expired - Fee Related
-
1996
- 1996-09-30 NZ NZ321616A patent/NZ321616A/en not_active IP Right Cessation
- 1996-10-30 CN CN96198786A patent/CN1124844C/zh not_active Expired - Fee Related
- 1996-10-30 CZ CZ19981231A patent/CZ287178B6/cs not_active IP Right Cessation
- 1996-10-30 EE EE9800123A patent/EE04293B1/xx not_active IP Right Cessation
- 1996-10-30 KR KR10-1998-0703325A patent/KR100367752B1/ko not_active IP Right Cessation
- 1996-10-30 WO PCT/FR1996/001706 patent/WO1997017064A1/fr active IP Right Grant
- 1996-10-30 JP JP51791297A patent/JP3357376B2/ja not_active Expired - Fee Related
- 1996-10-30 SK SK525-98A patent/SK283031B6/sk not_active IP Right Cessation
- 1996-10-30 CA CA002234140A patent/CA2234140C/fr not_active Expired - Fee Related
- 1996-10-30 EP EP96937367A patent/EP0858325B1/fr not_active Expired - Lifetime
- 1996-10-30 DK DK96937367T patent/DK0858325T3/da active
- 1996-10-30 IL IL12421496A patent/IL124214A/xx not_active IP Right Cessation
- 1996-10-30 PL PL96326451A patent/PL186284B1/pl not_active IP Right Cessation
- 1996-10-30 DE DE69622735T patent/DE69622735T2/de not_active Expired - Lifetime
- 1996-10-30 RU RU98110638/14A patent/RU2163801C2/ru not_active IP Right Cessation
- 1996-10-30 AU AU74990/96A patent/AU713383B2/en not_active Ceased
- 1996-10-30 AT AT96937367T patent/ATE221374T1/de active
- 1996-10-30 TR TR1998/00782T patent/TR199800782T2/xx unknown
- 1996-10-30 UA UA98062884A patent/UA60297C2/uk unknown
- 1996-10-30 BR BR9611367A patent/BR9611367A/pt not_active IP Right Cessation
- 1996-10-30 ES ES96937367T patent/ES2180805T3/es not_active Expired - Lifetime
- 1996-10-30 US US09/066,387 patent/US6284277B1/en not_active Expired - Lifetime
- 1996-10-30 PT PT96937367T patent/PT858325E/pt unknown
- 1996-10-31 ZA ZA9609176A patent/ZA969176B/xx unknown
- 1996-11-01 MY MYPI96004556A patent/MY116578A/en unknown
- 1996-11-01 AR ARP960104998A patent/AR004255A1/es active IP Right Grant
- 1996-11-22 TW TW085114410A patent/TW442295B/zh not_active IP Right Cessation
-
1998
- 1998-04-28 MX MX9803344A patent/MX9803344A/es unknown
- 1998-04-29 IS IS4729A patent/IS1967B/is unknown
- 1998-04-30 NO NO19981967A patent/NO322582B1/no not_active IP Right Cessation
-
1999
- 1999-03-02 HK HK99100839A patent/HK1015697A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR004255A1 (es) | Formulacion liofilizada farmaceuticamente aceptable constituida por una fase amorfa y una fase cristalina, que comprende por lo menos un principio activo no proteico, y procedimiento para estabilizar el principio activo no proteico contenido en la formulacion liofilizada farmaceuticamente aceptable | |
HUP9902679A2 (hu) | Készítmény emberen élősködő rovarok és atkák leküzdésére, ennek előállítása, valamint alkalmazása | |
ES2182357T3 (es) | Nueva utilizacion de budesonide y formoterol. | |
WO2001033966A3 (de) | Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften | |
ES2117015T3 (es) | Composiciones que contienen sumatriptan. | |
AR018109A1 (es) | FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA | |
ES2073205T3 (es) | Agentes con efecto refrigerante fisiologico y compuestos activos apropiados para estos agentes. | |
ES2088312T3 (es) | Formulacion de liberacion controlada que contiene tramadol. | |
BR9909266A (pt) | Formulações efervescentes | |
CA2164933A1 (en) | Methods for Aiding Periodontal Tissue Regeneration | |
FI973828A0 (fi) | Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi | |
AR007542A1 (es) | Composicion | |
IT1230742B (it) | Composizione per aerosol comprendente nitroglicerina come ingrediente attivo. | |
ES2158494T3 (es) | Caramelos que contienen un edulcorante. | |
ES2116804T3 (es) | Preparado polifasico para la anticoncepcion basado en estrogenos naturales. | |
ES2179193T3 (es) | Combinaciones sinergicas de zidovudina, 1592u89 y 3tc. | |
EP2275125A3 (en) | Protein-based streptococcus pneumoniae vaccines | |
ES2091001T3 (es) | Capsula que contiene un componente susceptible de degradacion y un polimero compuesto. | |
PE68899A1 (es) | Composicion que contiene paracetamol | |
IT1263840B (it) | Formulazioni orali di ubidecarenone in forma di capsule | |
ES2111163T3 (es) | Uso de fosfonatos para el tratamiento de la osteoporosis. | |
ES2089357T3 (es) | Formulacion medicinal en forma de aerosol. | |
IT1295289B1 (it) | Co-macinati per uso cosmetico e dermatologico | |
ES2082515T3 (es) | Composiciones de aseo. | |
BR9707770C1 (pt) | Tifluzamida com eficácia aperfeiçoada |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FG | Grant, registration |